Medicamen Organics Limited — Investor Meet, 10-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Medicamen has announced a board meeting to discuss the financial results for the quarter and half-year. H2 FY25 revenue grew 51% YoY to INR38.18 Cr, with PAT up 54% at INR4.04 Cr and EBITDA margin around 24%. The Haridwar plant is expanding capacity by 20%, currently running at 60–65%. Growth is driven by global expansion, including a 30% stake in a Nepal-based EU-compliant plant targeting Europe and Asia, with a potential INR400 Cr revenue. Exports (~70%) focus on Africa, supported by 120 product registrations. A new cosmetics vertical targets INR15 Cr revenue in FY26. High debtor days are managed through selective profiling and logistics. The outlook is confident, emphasizing export-led growth, product diversification, and margin improvement.